These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 22991923

  • 1. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
    Calza L, Trapani F, Salvadori C, Magistrelli E, Manfredi R, Colangeli V, Di Bari MA, Borderi M, Viale P.
    Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
    [Abstract] [Full Text] [Related]

  • 2. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
    Young J, Schäfer J, Fux CA, Furrer H, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC, Swiss HIV Cohort Study.
    AIDS; 2012 Mar 13; 26(5):567-75. PubMed ID: 22398568
    [Abstract] [Full Text] [Related]

  • 3. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
    Albini L, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, Izzo I, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Quiros-Roldan E, Manili L, Guaraldi G, Lapadula G, Torti C.
    J Acquir Immune Defic Syndr; 2012 Jan 01; 59(1):18-30. PubMed ID: 21992924
    [Abstract] [Full Text] [Related]

  • 4. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
    Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A, ARCA Collaborative Group.
    J Antimicrob Chemother; 2013 Jan 01; 68(1):200-5. PubMed ID: 22915463
    [Abstract] [Full Text] [Related]

  • 5. A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
    Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, Torres F, Mateo MG, Villarroya J, Lamarca K, Domingo JC, Vidal F, Villarroya F, Giralt M.
    J Acquir Immune Defic Syndr; 2014 Aug 15; 66(5):457-65. PubMed ID: 24820106
    [Abstract] [Full Text] [Related]

  • 6. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
    Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Wirtz V, Lataillade M, Absalon J, McGrath D, CASTLE Study Team.
    J Acquir Immune Defic Syndr; 2010 Mar 15; 53(3):323-32. PubMed ID: 20032785
    [Abstract] [Full Text] [Related]

  • 7. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
    Moyle GJ, Hardy H, Farajallah A, DeGrosky M, McGrath D.
    Clin Drug Investig; 2014 Apr 15; 34(4):287-96. PubMed ID: 24557728
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
    Edén A, Andersson LM, Andersson O, Flamholc L, Josephson F, Nilsson S, Ormaasen V, Svedhem V, Säll C, Sönnerborg A, Tunbäck P, Gisslén M.
    AIDS Res Hum Retroviruses; 2010 May 15; 26(5):533-40. PubMed ID: 20455766
    [Abstract] [Full Text] [Related]

  • 9. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
    Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S.
    Clin Infect Dis; 2012 Nov 15; 55(9):1262-9. PubMed ID: 22820542
    [Abstract] [Full Text] [Related]

  • 10. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E, Mills A, Bhatti L, Conner C, Storfer S.
    Int J Clin Pract; 2011 Dec 15; 65(12):1240-9. PubMed ID: 21999631
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS, Chang EY, Bentley TG, Juday T, Uy J.
    J Med Econ; 2011 Dec 15; 14(2):167-78. PubMed ID: 21288058
    [Abstract] [Full Text] [Related]

  • 12. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
    Gianotti N, Galli L, Poli A, Salpietro S, Nozza S, Carbone A, Merli M, Ripa M, Lazzarin A, Castagna A.
    Medicine (Baltimore); 2016 May 15; 95(22):e3780. PubMed ID: 27258510
    [Abstract] [Full Text] [Related]

  • 13. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
    Uy J, Yang R, Wirtz V, Sheppard L, Farajallah A, McGrath D.
    AIDS Care; 2011 Nov 15; 23(11):1500-4. PubMed ID: 21732894
    [Abstract] [Full Text] [Related]

  • 14. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
    Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu HC, Mathias AA, Chuck SL, Kearney BP, Warren DR, GS-US-216-0105 Study Team.
    AIDS; 2011 Sep 24; 25(15):1881-6. PubMed ID: 21811136
    [Abstract] [Full Text] [Related]

  • 15. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
    McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE.
    J Infect Dis; 2011 Jun 15; 203(12):1791-801. PubMed ID: 21606537
    [Abstract] [Full Text] [Related]

  • 16. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A, Cozzi-Lepri A, Antinori A, Zaccarelli M, Bongiovanni M, Di Giambenedetto S, Marconi P, Cicconi P, Resta F, Grisorio B, Ciardi M, Cauda R, Monforte Ad, I.Co.N.A, UCSC, IMIT-MI, INMI.
    Antivir Ther; 2006 Jun 15; 11(5):609-18. PubMed ID: 16964829
    [Abstract] [Full Text] [Related]

  • 17. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P.
    Expert Rev Anti Infect Ther; 2009 Sep 15; 7(7):801-5. PubMed ID: 19735222
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
    Zhu L, Liao S, Child M, Zhang J, Persson A, Sevinsky H, Eley T, Xu X, Krystal M, Farajallah A, McGrath D, Molina JM, Bertz R.
    J Antimicrob Chemother; 2012 Feb 15; 67(2):465-8. PubMed ID: 22121190
    [Abstract] [Full Text] [Related]

  • 19. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
    Calza L, Trapani F, Tedeschi S, Piergentili B, Manfredi R, Colangeli V, Viale P.
    Scand J Infect Dis; 2011 Aug 15; 43(8):656-60. PubMed ID: 21453205
    [Abstract] [Full Text] [Related]

  • 20. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
    Vrouenraets SM, Wit FW, Fernandez Garcia E, Moyle GJ, Jackson AG, Allavena C, Raffi F, Jayaweera DT, Mauss S, Katlama C, Fisher M, Slama L, Hardy WD, Dejesus E, van Eeden A, Reiss P, BASIC Study Group.
    HIV Med; 2011 Nov 15; 12(10):620-31. PubMed ID: 21819530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.